Personalized Lung Cancer Screening Tool Adds Asbestos Exposure

A University of Michigan and Veterans Affairs research team has developed a novel, personalized lung cancer screening tool that accounts for past asbestos exposure. Asbestos exposure is best known as the primary cause of mesothelioma, but it also significantly increases the chance of developing lung cancer. Adding asbestos to the lung-cancer screening tool also should help identify mesothelioma in its earliest stages, when it is most treatable. Mesothelioma is not usually diagnosed until it has progressed into stage 3 or stage 4, when treatment is more palliative than potentially curative. The tool is designed to better identify people who may benefit — and who won’t benefit — from low dose computed tomography (CT) screening for lung cancer. Early CT screening has become more popular in recent years, leading to a reduction in lung cancer mortality, yet it remains a controversial topic. More than 200,000 Americans are diagnosed with lung cancer each year, and it remains the leading cause of cancer death in the United States. Personalizing Lung Cancer Screening The innovative screening tool stems from a study the team published May 29 in the Annals of Internal Medicine. It details best practices for doctors to personalize lung cancer screening decisions for each patient. The study explores individual lung cancer risks along with potential benefits. It also explores patient attitudes concerning problems and consequences that could arise with screening. “...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Abstract Malignant pleural mesothelioma is an aggressive, deadly cancer often requiring input from multiple medical disciplines. Treatment has evolved over the last several decades with increasing evidence and ongoing advances in chemotherapy, radiation, and immunotherapy; however, no standard treatment regimen has yet been defined. Regardless of the overall strategy, surgery remains the foundation of treatment to remove macroscopic disease, and preservation of lung parenchyma via extended pleurectomy/decortication may be preferable to extrapleural pneumonectomy. PMID: 33012435 [PubMed - in process]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Thorac Surg Clin Source Type: research
Abstract Extrapleural pneumonectomy (EPP) is the most extensive form of surgery for mesothelioma, involving en bloc resection of visceral and parietal pleura, lung, diaphragm and pericardium, with reconstruction of the pericardium and diaphragm. It can be performed safely in carefully selected patients. It should be performed in experienced centers as part of a multimodality treatment plan. The SMART approach, with a short course of induction hemithoracic radiation followed by EPP has demonstrated safety and value of hypofractionated hemithoracic radiation combined with complete macroscopic resection. We are condu...
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Thorac Surg Clin Source Type: research
Abstract Staging of malignant pleural mesothelioma has been challenging because of a paucity of cases and poor survival. At least 5 staging systems were proposed before 1990 until the first consensus system was published in 1995. This system used tumor, node, metastasis designations and borrowed heavily from parenchymal lung cancer descriptors. With the establishment of a database to collect cases from 1995 to 2013, evidence-based revisions to the 1995 staging classification were published in 2016. With improving imaging technology, clinical staging will become more refined and, it is hoped, more useful for progno...
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Thorac Surg Clin Source Type: research
The U.S. Food and Drug Administration has approved the immunotherapy combination of Opdivo and Yervoy for first-line treatment of unresectable malignant pleural mesothelioma. It was the first new drug regimen approved for mesothelioma in 16 years and only the second systemic therapy ever. The historic treatment approval for this cancer without a cure was the first since the FDA approved the chemotherapy combination of pemetrexed and cisplatin in 2004. “This marks the beginning of a new era for mesothelioma,” Dr. Bernardo Goulart, medical oncologist at Seattle Cancer Care Alliance, told The Mesothelioma Center a...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Malignant pleural mesothelioma (MPM) is a rare and extremely aggressive tumor responsible for over 27,000 deaths per year worldwide ([1,2]). First-line therapeutic approaches include surgery, radiations, and chemotherapy ([2,3]). Regrettably, MPMs are refractory to standard treatments, as demonstrated by the short median overall survival rate (9.5 months) ([3]). A new possible treatment opportunity for MPM patients stems from the introduction of a new class of immunotherapeutic drugs, known as immune checkpoint inhibitors (ICI), that has changed the prognosis of several solid tumors ([2,4]).
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Primary tumour volume (T-volume) is a critical determinant of survival and a key component of Tumor, Node, Metastases (TNM) cancer staging. Simple surrogates of tumour volume, such as unidimensional measurements perform well in many cancers (e.g. Lung Cancer) [1], but Malignant Pleural Mesothelioma (MPM) forms a complex, rind-like primary tumor that is difficult to accurately measure. As a result, current T-staging describes only the extent of invasion into adjacent tissues and does not account for tumour size, and demonstrates poor concordance with subsequent pathological staging [2] and limited prognostic accuracy in &ls...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Angiogenesis is a complex process involving the interaction between tumour cells, growth factors and cells within the tumour microenvironment (TME). The purported primary stimulus for angiogenesis in the TME is the hypoxia-driven activation of hypoxia-inducible factor-1 α, and the subsequent activation of VEGF, along with many other growth factors including platelet derived growth factors, endothelial growth factors and fibroblast growth factor.1–3 The interaction between these cells within the TME and the supporting growth factors induce pro-inflammatory mediat ors which supports proliferation and survival of ...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
While the incidence of malignant mesothelioma in the United States continued its gradual decline, the tendency to sue for damages drastically increased in recent years, according to a KCIC study. Lawsuits filed by those stricken with the deadly asbestos-related cancer increased 65.7% from 2007 to 2017. Meanwhile, the overall incidence rate of mesothelioma dropped 16.2% during the same period. KCIC, a well-regarded consulting firm in Washington, D.C., that manages asbestos product liabilities, published the study of mesothelioma and asbestos litigation last week. Study author Megan Shockley, senior manager at KCIC, was unav...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
A research team at Oslo University Hospital in Norway has opened a mesothelioma clinical trial using the novel UV1 cancer vaccine alongside a promising immunotherapy combination. UV1 is a peptide-based vaccine designed to induce a specific T-cell response and increase the effectiveness of the immunotherapy drugs. This is the first time UV1 will be studied with mesothelioma cancer, but it already has shown safety and signs of efficacy when used on malignant melanoma, prostate cancer and lung cancer in studies worldwide. It will be used with the immunotherapy combination of nivolumab and ipilimumab, also known by brand names...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The objectives of this study were to monitor the levels of asbestos fibers in ambient air of Mashhad, Iran during 2018, and to draw its Geographic Information System (GIS) distribution map for the city. In this descriptive study, 13 sampling points in Mashhad city were chosen. Sampling of asbestos was carried out for 3 hour during summer and winter at 2018. Sampling of asbestos was performed using MCE (Mixed Cellulose Ester) membrane filters (pour size 0.45  µm; diameter: 25 mm) and cassette holder and peripheral pump. The samples were the analyzed by the phase contrast microscopy (PCM) method (NIOSH7400). ...
Source: Journal of Environmental Health Science and Engineering - Category: Environmental Health Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | CT Scan | Environmental Health | Internal Medicine | Learning | Lung Cancer | Mesothelioma | Palliative | PET Scan | Smokers | Study | Universities & Medical Training | USA Health